SECTOR
Dr. Reddy's Laboratories’ arm partners with Immutep’s wholly-owned subsidiary
Dec-08-2025

Dr. Reddy's Laboratories’ wholly-owned subsidiary -- Dr. Reddy’s Laboratories SA, has entered into a strategic collaboration and exclusive Licensing agreement with Immutep SAS, a wholly-owned subsidiary of Immutep for the development and commercialisation of Eftilagimod Alfa (efti) in all countries outside North America, Europe, Japan, and Greater China.  The terms of the licensing agreement provide Immutep significant milestones and preserve its ability to capture material future upside in the licensed markets as efti advances commercially. Further, Immutep holds the global manufacturing rights to the product across all markets and will supply the product to the company in the licensed markets, while it retains all rights to the product in the key pharmaceutical markets, including North America, Europe, and Japan. 

Additionally, as per the agreement, Immutep will receive an upfront payment of $20 million (around 30.2 million Australian Dollar (AUD)) from the company. It is also eligible to receive potential regulatory development and commercial milestone payments of up to $349.5 million (around 528.4 million AUD), plus double-digit royalties on commercial sales in these markets. Efti is Immutep’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Efti is also being investigated in other indications including head & neck cancer, breast cancer, and soft tissue sarcoma.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

  RELATED NEWS >>